NCT06729320View on ClinicalTrials.gov

A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
Refractory Immune Effector Cell-related Hemocytopenia
Interventions
BIOLOGICAL

Umbilical cord blood mononuclear cells

Intravenous infusion of UCB-MNCs (3×10\^8/ time, once a week, four times in total)

COMBINATION_PRODUCT

Conventional hematopoietic recovery therapy

Including but not limited to G-CSF, TPO, TPO receptor agonists, transfusions of red blood cells, platelets, etc.

Trial Locations (1)

102200

Beijing GoBroad Hospital, Beijing

All Listed Sponsors
lead

Beijing GoBroad Hospital

OTHER

NCT06729320 - A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia | Biotech Hunter | Biotech Hunter